Novel Bioengineering approaches for studying muscle tissue homeostasis and regeneration.

Stefano Eriani
Stefano ErianiDepartment of biomedical engineering - Technion Research & Development Foundation Ltd

I am a PhD student at Technion University, Israel, as part of the RENOIR programme.
I have a B.Sc. in Biotechnology and a M.Sc. in Medical Biotechnology from University of Milano Bicocca, Italy.
During My master’s Thesis I worked on the “Validation Of New Markers For The Identification In Situ Of Human Adult Renal Stem Cells”.
I am enrolled for my PhD to the interdisciplinary program of Biotechnology at Technion University. During my project I will focus on guiding myoblasts towards myogenic differentiation using hydrogel stiffness and Cripto signaling. The aim is to investigate each of these mechanisms both individually and together, using a set of in vitro and in vivo experiments. The final goal is to advance the knowledge and to find the best way for the delivery, survival and myogenic differentiation of satellite cells when treating muscle disease.

Technion Israel Institute of Technology

Technion Research & Development Foundation Ltd.



It is well known that extracellular stimuli from the microenvironment are crucial for cell adhesion, migration, proliferation and differentiation, and the ECM constitutes the very foundation of tissue homeostasis and development.

Despite this, the analysis of such cells/ECM interplays in vivo is hampered by the intrinsic complexity of the native environment. To overcome this limitation, we will we will use of a specific biosynthetic protein-polymer hydrogel as an ECM-analogue for culturing cells in 3D, with highly defined and precisely controllable density, microarchitecture, proteolytic susceptibility, compliance and bio functionality.

We will use this method to elucidate the dominant and influential physical factors affecting morphogenesis patterns, phenotypic states, and differentiation of various muscle progenitor cell types and will further identify the optimal environmental conditions for directing stem cells in vivo based on biophysical induction and mechanical stimulation.

We will also engineering bioactive materials and devices to reconstruct the muscle niche in vitro. Innovative biomaterials will also be exploited to optimize the in vivo delivery of either stem/progenitor cells or biological drugs in animal models of muscle diseases. In vivo administration of proteins/biological drugs require to: i) enable the protein to maintain its structure and activity over a prolonged period of time, and ii) control the release kinetics allowing the appropriate dose of protein to reach the site over a given period of time. We will use semi-synthetic biomaterials made by grafting synthetic polymers onto proteins such as collagen and fibrinogen in order to create stable, elastic gels.

The biosynthetic gels are inherently biocompatible and proteolytically degradable based on their protein backbone, making them amenable to cell-mediated remodelling and morphogenesis. The conjugated polymer provides exact control over the hydrogel’s material properties. Injectable polymer/protein biomaterials will be used to deliver different biopharma, in a controlled fashion. They will evaluate the optimal condition for in vivo delivery of the biological drugs in mouse models of acute (CTX) and chronic injury (mdx mice) and assess their ability to improve muscle regeneration and eventually ameliorate the disease phenotype.

  • To use novel bioengineering approaches to elucidate the dominant and influential physical factors affecting proliferation/differentiation of different progenitor cells in muscle regeneration

  • To engineer biomaterial delivery vehicle for temporal and spatial control of therapeutic proteins/cells in muscle regeneration











Meet Our Team


Latest News